Haisco Pharmaceutical Group (002653.SZ): New indication for innovative drug HSK21542 injection approved for market authorization application.

Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary, Liaoning Haisco Pharmaceutical Group Pharmaceutical Co., Ltd., received a "Notice of Acceptance" from the National Medical Products Administration on September 23, 2024. The drug name is HSK21542 injection. HSK21542 injection is a highly selective and specific agonist of the peripheral kappa opioid receptor (KOR) developed independently by the company. It has high selectivity and affinity and regulates potassium and calcium ion currents through G-protein involvement, blocking pain and itch signals transmission. By inhibiting the excitability of the dorsal root ganglia and peripheral sensory nerves, reducing inflammatory factors and neurotransmitter release, it has analgesic and anti-itch effects. This product does not pass the blood-brain barrier. While exerting peripheral analgesic and anti-itch effects, it can avoid central opioid-related side effects such as hallucinations, addiction, and respiratory depression.